Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Sanofi to sell Japanese manufacturing plant

0
SHARES

Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.

Sanofi building

credit: nitpicker / Shutterstock.com

Sanofi has signed definitive agreements with Adragos Pharmaceutical, a German contract development and manufacturing organisation (CDMO), for the sale of its pharmaceutical manufacturing site in Kawagoe, Japan.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The French pharmaceutical company will also enter into a long-term supply agreement with the CDMO. The goal is for the CDMO to become a strategic partner to introduce new European, North American and Japanese customers to the manufacturing plant.

Sanofi’s International & Europe Cluster Head of Industrial Affairs, Jeremy Goldnadel declared: “We are delighted to work as strategic partner…and continue delivering the highest quality products in the long term and further develop the manufacturing site.”

Historically, the 50-year-old site produced oral solids, sterile liquids, packaged products and offered retesting services to the Japanese and Asian markets.

Both parties said they intend to use the facility as a platform for future growth and to ensure the site provides a reliable supply of affordable products.

Sanofi states its work currently focuses on the research and development of vaccines, therapies for immunological, oncological and neurological disorders and medicines for rare diseases. Conditions include type 1 diabetes, cancer, rheumatoid arthritis and Gaucher disease. For progressive conditions like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), the group aim to create high-quality therapies that slow or stop neurodegeneration, control neuroinflammation and protect the nervous system.

The business also works to deliver medication to low-income countries, expanding its reach worldwide. In April 2021, Sanofi Global Health was created to boost healthcare access in 40 countries, by improving the distribution of therapies and enhancing healthcare systems in regions with low incomes. According to the company, its project is the first and only one to offer such a wide scope: from the quantity of available medicines to the number of countries and therapeutic areas it covers. 

Share via
Share via